Jane Street Group, LLC Lineage Cell Therapeutics, Inc. Transaction History

Jane Street Group, LLC

  • $445 Billion
  • Q3 2024

A detailed history of Jane Street Group, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 119,901 shares of LCTX stock, worth $64,746. This represents 0.0% of its overall portfolio holdings.

Number of Shares
119,901
Previous 242,955 50.65%
Holding current value
$64,746
Previous $242,000 54.96%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$0.8 - $1.12 $98,443 - $137,820
-123,054 Reduced 50.65%
119,901 $109,000
Q2 2024

Aug 14, 2024
BUY
$0.89 - $1.47 $122,957 - $203,087
138,155 Added 131.83%
242,955 $242,000
Q1 2024

May 15, 2024
SELL
$0.86 - $1.48 $50,921 - $87,632
-59,211 Reduced 36.1%
104,800 $155,000
Q4 2023

Feb 14, 2024
BUY
$0.91 - $1.35 $110,981 - $164,643
121,958 Added 290.01%
164,011 $178,000
Q3 2023

Nov 14, 2023
BUY
$1.16 - $1.53 $21,614 - $28,508
18,633 Added 79.56%
42,053 $49,000
Q2 2023

Aug 14, 2023
SELL
$1.26 - $1.53 $722,010 - $876,726
-573,024 Reduced 96.07%
23,420 $33,000
Q1 2023

May 15, 2023
BUY
$1.2 - $1.53 $546,238 - $696,454
455,199 Added 322.28%
596,444 $894,000
Q4 2022

Feb 14, 2023
BUY
$1.02 - $1.5 $109,367 - $160,834
107,223 Added 315.16%
141,245 $165,000
Q3 2022

Nov 14, 2022
SELL
$1.13 - $1.77 $28,199 - $44,170
-24,955 Reduced 42.31%
34,022 $38,000
Q2 2022

Aug 16, 2022
SELL
$1.12 - $1.61 $73,060 - $105,025
-65,233 Reduced 52.52%
58,977 $93,000
Q1 2022

May 17, 2022
SELL
$1.21 - $2.48 $171,657 - $351,827
-141,866 Reduced 53.32%
124,210 $191,000
Q4 2021

Feb 15, 2022
BUY
$1.84 - $2.68 $374,489 - $545,452
203,527 Added 325.39%
266,076 $652,000
Q3 2021

Nov 16, 2021
SELL
$2.26 - $2.86 $374,068 - $473,378
-165,517 Reduced 72.57%
62,549 $158,000
Q2 2021

Aug 16, 2021
BUY
$2.17 - $3.0 $341,829 - $472,575
157,525 Added 223.31%
228,066 $650,000
Q1 2021

May 18, 2021
BUY
$1.77 - $3.1 $70,492 - $123,460
39,826 Added 129.66%
70,541 $166,000
Q4 2020

Feb 17, 2021
SELL
$0.95 - $1.83 $145,373 - $280,035
-153,025 Reduced 83.28%
30,715 $54,000
Q3 2020

Nov 17, 2020
SELL
$0.75 - $1.09 $609,386 - $885,641
-812,515 Reduced 81.56%
183,740 $172,000
Q2 2020

Aug 17, 2020
BUY
$0.71 - $1.18 $572,475 - $951,438
806,304 Added 424.48%
996,255 $867,000
Q1 2020

May 15, 2020
BUY
$0.6 - $1.58 $84,889 - $223,543
141,483 Added 291.91%
189,951 $157,000
Q4 2019

Feb 14, 2020
BUY
$0.54 - $1.01 $12,042 - $22,523
22,300 Added 85.22%
48,468 $43,000
Q3 2019

Nov 14, 2019
BUY
$0.85 - $1.24 $22,242 - $32,448
26,168 New
26,168 $26,000

Others Institutions Holding LCTX

# of Institutions
120
Shares Held
94.2M
Call Options Held
63.8K
Put Options Held
1K
View Full List

About Lineage Cell Therapeutics, Inc.

LCTX Quotes by TradingView
  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $91.7M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email